IP Library Granted Patent US 11,452,712
Granted Patent B2
US 11,452,712 · App. 16/219,722 · Granted Sep 27, 2022

Methods and compositions involving (S)-bucindolol

Inventors: Michael R. Bristow (Englewood, CO); Jonathan D. Port (Denver, CO)
Assignee: Arca Biopharma Inc.
A61K31/4045A61B17/04A61B17/1214A61B17/72A61B17/80A61B17/86A61F2/0063A61F2/06A61F2/82A61K45/06A61L27/54A61L29/16A61L31/16A61M25/0045C07D209/14A61F2250/0067A61L2300/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,452,712
App. No.
16/219,722
Granted
Sep 27, 2022
Kind
B2
Abstract

Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Claims (8)

1. A medical device comprising a coating, a matrix, or a chamber, wherein said coating, matrix, or chamber comprises bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the coating, matrix, or chamber is at least about 99:1 by weight.

2. The medical device of claim 1 , wherein the medical device is a stent, a graft, a heart valve, a filter, a catheter, a coil, a mesh repair material, a plate, a rod, a screw, or a suture.

3. The medical device of claim 1 , wherein the medical device is a stent comprising a coating comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the coating is at least about 99:1 by weight.

4. The medical device of claim 1 , wherein the medical device is a stent comprising a matrix comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the matrix is at least about 99:1 by weight.

5. The medical device of claim 1 , wherein the medical device is a stent comprising a chamber comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the chamber is at least about 99:1 by weight.

6. The medical device of claim 1 , wherein the medical device is a graft comprising a coating comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the coating is at least about 99:1 by weight.

7. The medical device of claim 1 , wherein the medical device is a graft comprising a matrix comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the matrix is at least about 99:1 by weight.

8. The medical device of claim 1 , wherein the medical device is a graft comprising a chamber comprising said bucindolol substantially free of the R-stereoisomer of said bucindolol, wherein the ratio of S-bucindolol to R-bucindolol in the chamber is at least about 99:1 by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2024
From: ARCA BIOPHARMA, INC.
To: GENVARA BIOPHARMA, INC.
Reel/Frame 069506/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2019
From: BRISTOW, MICHAEL R.; PORT, JONATHAN D.
To: ARCA BIOPHARMA, INC.
Reel/Frame 050456/0052 →
Continuity (6)
Continuation 15707557 · Sep 18, 2017
Division 15268137 · Sep 16, 2016
Continuation 14590661 · Jan 6, 2015
Division 13056916
Provisional Application 61085586 · Aug 1, 2008
Related Publication 20190358204A1 · Nov 28, 2019